Persistent Efficacy of Dextromethorphan (DM)/Quinidine (Q) for Pseudobulbar Affect (PBA): Results from a 12-Week, Open-Label Extension (OLE) Study

被引：0
|
作者：
Pioro, Erik
Brooks, Benjamin
Cummings, Jeffrey
Schiffer, Randolph
Wynn, Daniel
Hepner, Adrian
Kaye, Randall
机构：
来源：
NEUROLOGY | 2010年 / 75卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：380 / 380
页数：1
相关论文
共 50 条
  • [1] Persistence of Effect of Dextromethorphan Hydrobromide/Quinidine Sulfate (DM/Q) for Pseudobulbar Affect (PBA): Results from a 12-Week Open-Label Extension (OLE) Study
    Brooks, Benjamin Rix
    Pioro, Erik P.
    Shin, Paul
    Law, Ryan
    Formella, Andrea E.
    NEUROLOGY, 2017, 88
  • [2] Safety and Tolerability of Dextromethorphan/Quinidine for Pseudobulbar Affect in a 12-Week, Open-Label Extension Study
    Pioro, Erik
    Brooks, Benjamin
    Cummings, Jeffrey
    Schiffer, Randolph
    Wynn, Daniel
    Hepner, Adrian
    Viejo, Aliso
    Kaye, Randall
    NEUROLOGY, 2010, 74 (09) : A541 - A541
  • [3] An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results
    Doody, Rachelle S.
    D'Amico, Stephen
    Cutler, Andrew J.
    Davis, Charles S.
    Shin, Paul
    Ledon, Fred
    Yonan, Charles
    Siffert, Joao
    CNS SPECTRUMS, 2016, 21 (06) : 450 - 459
  • [4] Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study
    Dougados, Maxime
    Braun, Jurgen
    Szanto, Sandor
    Combe, Bernard
    Geher, Pal
    Leblanc, Veronique
    Logeart, Isabelle
    RHEUMATOLOGY, 2012, 51 (09) : 1687 - 1696
  • [5] Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study
    Miura, Itaru
    Watabe, Kei
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Maruyama, Hidenori
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 2627 - 2637
  • [6] An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions
    Pattee, Gary L.
    Wymer, James P.
    Lomen-Hoerth, Catherine
    Appel, Stanley H.
    Formella, Andrea E.
    Pope, Laura E.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (11) : 2255 - 2265
  • [7] Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
    Iyo, Masaomi
    Ishigooka, Jun
    Nakamura, Masatoshi
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Mao, Yongcai
    Tsai, Joyce
    Fitzgerald, Alison
    Takai, Kentaro
    Higuchi, Teruhiko
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 2683 - 2695
  • [8] LURASIDONE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER WITH MIXED FEATURES: RESULTS OF A 12-WEEK OPEN-LABEL EXTENSION STUDY
    Stahl, S. M.
    Pikalov, A.
    Tocco, M.
    Mao, Y.
    Loebel, A.
    Hopwood, M.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 145 - 146
  • [9] Lurasidone for the treatment of major depressive disorder with mixed features: results of a 12-week open-label extension study
    Stahl, S. M.
    Pikalov, A.
    Tocco, M.
    Mao, Y.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2019, 56 : S94 - S94
  • [10] PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
    Flora M. Hammond
    David N. Alexander
    Andrew J. Cutler
    Stephen D’Amico
    Rachelle S. Doody
    William Sauve
    Richard D. Zorowitz
    Charles S. Davis
    Paul Shin
    Fred Ledon
    Charles Yonan
    Andrea E. Formella
    Joao Siffert
    BMC Neurology, 16
12345